ERBB2 and breast carcinoma: For instance, the hetero-interaction between AXL and human epidermal growth factor receptor 2 (HER2) leads to downstream PI3K/AKT and ERK signalling and allows cells to evade the inhibitory effects of lapatinib in HER2-positive breast cancer [123].